Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
$0.74
-10.7%		$1.24
$0.55
▼
$10.00
$19.58M0.7347,689 shs72,950 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.14
-2.6%		$1.26
$0.84
▼
$2.46
$19.51M1.5384,149 shs35,858 shs
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
$3.39
+2.1%		$3.50
$1.83
▼
$24.60
$19.18M0.947,806 shs4,644 shs
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
$0.84
+28.5%		$0.78
$0.51
▼
$34.65
$4.90M0.33808,890 shs5.99 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
-10.70%-15.04%-41.17%-55.88%-75.69%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-2.56%-5.79%-1.72%-14.29%+14.60%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
+2.11%+4.31%+3.99%+2.42%-84.01%
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
0.00%0.00%0.00%0.00%-85.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
$0.74
-10.7%		$1.24
$0.55
▼
$10.00
$19.58M0.7347,689 shs72,950 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.14
-2.6%		$1.26
$0.84
▼
$2.46
$19.51M1.5384,149 shs35,858 shs
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
$3.39
+2.1%		$3.50
$1.83
▼
$24.60
$19.18M0.947,806 shs4,644 shs
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
$0.84
+28.5%		$0.78
$0.51
▼
$34.65
$4.90M0.33808,890 shs5.99 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
-10.70%-15.04%-41.17%-55.88%-75.69%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-2.56%-5.79%-1.72%-14.29%+14.60%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
+2.11%+4.31%+3.99%+2.42%-84.01%
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
0.00%0.00%0.00%0.00%-85.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
1.00
SellN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
2.25
Hold$10.00777.19% Upside
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
2.00
Hold$23.00578.47% Upside
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest SLRX, GNTA, MRKR, and NCEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/2/2026
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/21/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/21/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/17/2026
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/6/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/30/2026
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/13/2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
7/13/2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
Laidlaw logo
Laidlaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$23.00
7/10/2026
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/29/2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E)
(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
N/AN/AN/AN/A$1.29 per shareN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$3.55M5.35N/AN/A$1.01 per share1.13
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/AN/AN/AN/A$1.59 per shareN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
N/AN/AN/AN/A$14.31 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
-$7.39MN/AN/AN/AN/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$12.16M-$0.41N/AN/AN/A-343.03%-56.96%-47.82%11/12/2026 (Estimated)
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
-$8.30MN/AN/AN/AN/AN/AN/AN/AN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
-$5.58M-$33.89N/AN/AN/AN/A-401.05%-155.77%N/A

Latest SLRX, GNTA, MRKR, and NCEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.25-$0.09+$0.16-$0.09$0.68 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/AN/AN/AN/AN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
0.35
14.16
14.16
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
6.03
6.03
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/A
0.76
0.76
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
N/A
3.28
3.28

Institutional Ownership

CompanyInstitutional Ownership
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
15.13%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
22.39%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
11.88%

Insider Ownership

CompanyInsider Ownership
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
28.99%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
5.70%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
16.40%
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
0.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
723.59 million16.75 millionNot Optionable
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6016.67 million15.72 millionNot Optionable
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
65.78 million4.83 millionNot Optionable
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
205.86 million5.84 millionNot Optionable

Recent News About These Companies

Salarius Pharmaceuticals, Inc. Common Stock (SLRX) Insider Activity
April 3, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/slrx/insider-activity
Salarius to Change Name
January 7, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/22425/Salarius-to-Change-Name
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics
January 7, 2026  |  in.investing.comhttps://in.investing.com/news/stock-market-news/salarius-pharmaceuticals-stock-soars-on-name-change-to-decoy-therapeutics-93CH-5176916
Salarius shares jump after rebranding announcement to Decoy Therapeutics
January 7, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/salarius-shares-jump-after-rebranding-announcement-to-decoy-therapeutics/ar-AA1TKPJ5
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
January 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/07/3214543/0/en/salarius-pharmaceuticals-changes-corporate-name-to-decoy-therapeutics-and-nasdaq-ticker-symbol-to-dcoy-reflecting-focus-on-next-generation-peptide-conjugate-therapeutics.html
Salarius shareholders back directors, executive pay and auditor
January 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/salarius-shareholders-back-directors-executive-pay-and-auditor/ar-AA1TtVIq
Salarius shareholders back directors, executive pay and auditor
January 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/salarius-shareholders-back-directors-executive-pay-and-auditor/ar-AA1TtVIq
Salarius Pharmaceuticals appeals Nasdaq delisting after bid deficiency
January 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/salarius-pharmaceuticals-appeals-nasdaq-delisting-after-bid-deficiency/ar-AA1TtrOD
Salarius Pharmaceuticals appeals Nasdaq delisting after bid deficiency
January 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/salarius-pharmaceuticals-appeals-nasdaq-delisting-after-bid-deficiency/ar-AA1TtrOD
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
December 19, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/19/3208629/0/en/salarius-pharmaceuticals-announces-adjournment-of-annual-meeting-information-for-reconvened-annual-meeting.html
Salarius announces planned corporate name change to Decoy Therapeutics
December 18, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/salarius-announces-planned-corporate-name-change-to-decoy-therapeutics/ar-AA1SBJuX
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide ...
December 18, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/salarius-pharmaceuticals-announces-planned-corporate-125000693.html
Salarius Pharmaceuticals, Inc. Transforms into Decoy Therapeutics, Inc. with NASDAQ Ticker Change to DCOY Effective January 2026
December 18, 2025  |  quiverquant.comQ
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
December 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/18/3207623/0/en/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjuga.html
Salarius Pharmaceuticals, Texas Biomed collaborate on Avian Flu study
December 1, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/salarius-pharmaceuticals-texas-biomed-collaborate-on-avian-flu-study/ar-AA1Rv8M9
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
December 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/01/3196958/0/en/salarius-pharmaceuticals-to-collaborate-with-texas-biomedical-research-institute-on-avian-flu-study.html
Salarius Pharmaceuticals (NASDAQ:SLRX) CFO Purchases $16,000.00 in Stock
November 21, 2025  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-slrx-insider-buying-and-selling-2025-11-21/
Salarius Pharmaceuticals affirms shares continue to trade on the Nasdaq
November 20, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/salarius-pharmaceuticals-affirms-shares-continue-to-trade-on-the-nasdaq/ar-AA1QLjuG
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the ...
November 19, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/salarius-pharmaceuticals-cites-errors-on-s-p-capiq-platform-following-merger-with-decoy-therapeutics-affirms-its-shares-continue-to-trade-on-the-nasdaq-stock-market-under-the-symbol-slrx-1035579035
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
November 19, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/11/19/3191374/0/en/salarius-pharmaceuticals-cites-errors-on-s-p-capiq-platform-following-merger-with-decoy-therapeutics-affirms-its-shares-continue-to-trade-on-the-nasdaq-stock-market-under-the-symbo.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Genenta Science stock logo

Genenta Science NASDAQ:GNTA

$0.74 -0.09 (-10.70%)
Closing price 09/16/2026 03:59 PM Eastern
Extended Trading
$0.74 0.00 (-0.58%)
As of 04:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$1.14 -0.03 (-2.56%)
Closing price 09/16/2026 04:00 PM Eastern
Extended Trading
$1.15 +0.01 (+1.23%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

NLS Pharmaceutics stock logo

NLS Pharmaceutics NASDAQ:NCEL

$3.39 +0.07 (+2.11%)
As of 09/16/2026 03:59 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Salarius Pharmaceuticals stock logo

Salarius Pharmaceuticals NASDAQ:SLRX

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas